Yatin Suneja
Stock Analyst at Guggenheim
(3.78)
# 747
Out of 4,980 analysts
138
Total ratings
53.72%
Success rate
7.26%
Average return
Main Sectors:
Stocks Rated by Yatin Suneja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Downgrades: Neutral | $55 → $48 | $47.60 | +0.84% | 4 | Sep 10, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $92 → $100 | $37.90 | +163.85% | 2 | Sep 9, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | $75 | $10.79 | +595.41% | 1 | Aug 18, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $25 → $15 | $1.74 | +762.07% | 6 | Aug 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $810 → $815 | $555.83 | +46.63% | 7 | Aug 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $165 → $175 | $141.25 | +23.89% | 6 | Aug 1, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,060 → $1,070 | $763.72 | +40.10% | 12 | Aug 1, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Buy | $50 → $101 | $87.63 | +15.26% | 2 | Jul 23, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Buy | $26 | $4.00 | +550.00% | 6 | Jun 25, 2025 | |
| ALMS Alumis | Reinstates: Buy | $18 | $4.30 | +318.60% | 2 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $90 | $22.75 | +295.60% | 13 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $29 | $12.89 | +124.98% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $12.32 | -2.60% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $2.06 | +628.16% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $1.58 | +532.91% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.80 | +771.51% | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $16.20 | - | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $19.79 | +127.39% | 3 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.63 | - | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $45 | $11.84 | +280.23% | 3 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $23.80 | -15.97% | 6 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.78 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $65 | $16.18 | +301.73% | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $155 → $170 | $40.21 | +322.78% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.14 | - | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $90 | $24.96 | +260.58% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $125 | $124.12 | +0.71% | 8 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $16 | $13.77 | +16.19% | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $77 | $54.20 | +42.07% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.56 | - | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $37.11 | +32.04% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $55 | $13.55 | +305.90% | 2 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $270 → $350 | $142.61 | +145.42% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.61 | - | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $15.00 | +60.00% | 1 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $106.37 | -68.04% | 2 | Jan 14, 2020 |
Tourmaline Bio
Sep 10, 2025
Downgrades: Neutral
Price Target: $55 → $48
Current: $47.60
Upside: +0.84%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $92 → $100
Current: $37.90
Upside: +163.85%
Forte Biosciences
Aug 18, 2025
Initiates: Buy
Price Target: $75
Current: $10.79
Upside: +595.41%
Cabaletta Bio
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $1.74
Upside: +762.07%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Buy
Price Target: $810 → $815
Current: $555.83
Upside: +46.63%
Neurocrine Biosciences
Aug 1, 2025
Maintains: Buy
Price Target: $165 → $175
Current: $141.25
Upside: +23.89%
argenx SE
Aug 1, 2025
Maintains: Buy
Price Target: $1,060 → $1,070
Current: $763.72
Upside: +40.10%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Buy
Price Target: $50 → $101
Current: $87.63
Upside: +15.26%
Larimar Therapeutics
Jun 25, 2025
Reiterates: Buy
Price Target: $26
Current: $4.00
Upside: +550.00%
Alumis
Jun 10, 2025
Reinstates: Buy
Price Target: $18
Current: $4.30
Upside: +318.60%
May 28, 2025
Maintains: Buy
Price Target: $54 → $90
Current: $22.75
Upside: +295.60%
May 9, 2025
Maintains: Buy
Price Target: $32 → $29
Current: $12.89
Upside: +124.98%
May 2, 2025
Maintains: Buy
Price Target: $18 → $12
Current: $12.32
Upside: -2.60%
Mar 26, 2025
Reiterates: Buy
Price Target: $15
Current: $2.06
Upside: +628.16%
Mar 26, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $1.58
Upside: +532.91%
Mar 21, 2025
Reiterates: Buy
Price Target: $7
Current: $0.80
Upside: +771.51%
Mar 20, 2025
Reiterates: Buy
Price Target: n/a
Current: $16.20
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $45
Current: $19.79
Upside: +127.39%
Mar 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.63
Upside: -
Jan 3, 2025
Upgrades: Buy
Price Target: $45
Current: $11.84
Upside: +280.23%
Jan 3, 2025
Downgrades: Neutral
Price Target: $20
Current: $23.80
Upside: -15.97%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.78
Upside: -
Oct 25, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $16.18
Upside: +301.73%
Aug 14, 2024
Maintains: Buy
Price Target: $155 → $170
Current: $40.21
Upside: +322.78%
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.14
Upside: -
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $24.96
Upside: +260.58%
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $124.12
Upside: +0.71%
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $13.77
Upside: +16.19%
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $54.20
Upside: +42.07%
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.56
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $37.11
Upside: +32.04%
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $13.55
Upside: +305.90%
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $142.61
Upside: +145.42%
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $15.00
Upside: +60.00%
Jan 14, 2020
Maintains: Buy
Price Target: $29 → $34
Current: $106.37
Upside: -68.04%